EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread

Carmen Criscitiello, Chiara Corti, Michelino De Laurentiis, Giampaolo Bianchini, Barbara Pistilli, Saverio Cinieri, Lucio Castellan, Grazia Arpino, Pierfranco Conte, Francesco Di Meco, Alessandra Gennari, Valentina Guarneri und 8 weitere

Cancer Treatment Reviews · 2023

DOI: 10.1016/j.ctrv.2023.102618 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Carmen Criscitiello und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncolog…. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrain NeoplasmsHumansFemaleQuality of LifeNeoplasm Recurrence, LocalTrastuzumabErb-b2 Receptor Tyrosine KinasesBrainAntineoplastic Combined Chemotherapy ProtocolsRandomized Controlled Trials as TopicOxazolesPyridinesQuinazolines

Stichwörter der Autor:innen

Brain metastasisBreast cancerDrug developmentHER2InnovationTKITucatinib

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasestucatinibOxazolesPyridinesQuinazolines

Autor:innen und Institutionen

  • Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy. E…
  • Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
  • Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Napoli, Italy.
  • Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Italy.

Zitieren

APA

Criscitiello, C., Corti, C., De Laurentiis, M., Bianchini, G., Pistilli, B., Cinieri, S., Castellan, L., Arpino, G., Conte, P., Di Meco, F., Gennari, A., Guarneri, V., Visani, L., Livi, L., Marchetti, P., Puglisi, F., Viale, G., Del Mastro, L., De Placido, S., & Curigliano, G. (2023). Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102618

Vancouver

Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, et al. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102618

BibTeX
@article{Criscitiello2023,
  author = {Criscitiello, Carmen and Corti, Chiara and De Laurentiis, Michelino and Bianchini, Giampaolo and Pistilli, Barbara and Cinieri, Saverio and Castellan, Lucio and Arpino, Grazia and Conte, Pierfranco and Di Meco, Francesco and Gennari, Alessandra and Guarneri, Valentina and Visani, Luca and Livi, Lorenzo and Marchetti, Paolo and Puglisi, Fabio and Viale, Giuseppe and Del Mastro, Lucia and De Placido, Sabino and Curigliano, Giuseppe},
  title = {Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  doi = {10.1016/j.ctrv.2023.102618}
}
Kostenlos starten →